Phenotypic Drug Resistance Patterns among Mycobacterium tuberculosis Isolates at the National Tuberculosis Reference Laboratory, Zambia, 2021–2025
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Drug-resistant tuberculosis (DR-TB) remains an important challenge to TB control, and characterization of phenotypic resistance patterns is essential for surveillance and appropriate treatment. However, routine laboratory data on resistance to individual first-line anti-TB drugs and specific resistance patterns among isolates referred to the National Tuberculosis Reference Laboratory (NTRL), Zambia, have not been recently described. This study characterized phenotypic resistance patterns and factors associated with multidrug-resistant tuberculosis (MDR-TB) among Mycobacterium tuberculosis isolates processed at the NTRL. Methods A retrospective laboratory-based observational study was conducted using routinely collected NTRL laboratory data between 1 January 2021 and 31 December 2025. Culture-confirmed M. tuberculosis isolates from patients with phenotypic drug susceptibility testing (DST) results for isoniazid, rifampicin, streptomycin and ethambutol were included. Resistance patterns were classified as fully susceptible, monoresistant, polyresistant non-MDR, or MDR-TB. Logistic regression was used to assess factors associated with MDR-TB. Crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. The adjusted model included age, sex, HIV status and previous treatment. Results A total of 172 M. tuberculosis isolates from 172 patients were included. Overall, 76 (44.19%) isolates were resistant to at least one drug. Resistance was highest for isoniazid (64/172, 37.21%; 95% CI: 30.25–44.75), followed by rifampicin (40/172, 23.26%; 95% CI: 17.49–30.22), streptomycin (22/172, 12.79%; 95% CI: 8.54–18.73) and ethambutol (18/172, 10.47%; 95% CI: 6.66–16.06). 96 (55.81%) isolates were fully susceptible, 31 (18.02%) showed monoresistance, 13 (7.56%) showed polyresistance without MDR-TB, and 32 (18.60%) were MDR-TB. Previous second-line treatment was independently associated with MDR-TB (aOR 5.29, 95% CI: 1.77–15.87; P = 0.003). HIV status, sex and age were not significantly associated with MDR-TB. Conclusion A substantial proportion of M. tuberculosis isolates referred to the NTRL showed resistance to first-line anti-TB drugs, with isoniazid resistance being the most common and MDR-TB identified in 18.60% of isolates. Previous second-line treatment was independently associated with MDR-TB. Continued phenotypic DST and routine laboratory surveillance are important for characterizing resistance patterns and supporting the management of DR-TB in Zambia.
Source: Research Square
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7226030890
